National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

This is VAERS ID 365938

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 12/8/2009

VAERS ID: 365938
VAERS Form:
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 2 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 9/14/2017

VAERS ID: 365938 Before After
VAERS Form:(blank) 1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 2 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 2/14/2018

VAERS ID: 365938 Before After
VAERS Form:1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 6/14/2018

VAERS ID: 365938 Before After
VAERS Form:1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 8/14/2018

VAERS ID: 365938 Before After
VAERS Form:1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 9/14/2018

VAERS ID: 365938 Before After
VAERS Form:1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 10/14/2018

VAERS ID: 365938 Before After
VAERS Form:1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 12/24/2020

VAERS ID: 365938 Before After
VAERS Form:1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 12/30/2020

VAERS ID: 365938 Before After
VAERS Form:1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 5/7/2021

VAERS ID: 365938 Before After
VAERS Form:1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.


Changed on 5/21/2021

VAERS ID: 365938 Before After
VAERS Form:1
Age:25.0
Sex:Female
Location:Foreign
Vaccinated:2009-06-30
Onset:2009-07-16
Submitted:2009-11-06
Entered:2009-11-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Typhoid fever

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0602071A

Write-up: This female subject was enrolled in a post-marketing surveillance open study 108160. On 29 January 2009, 03 March 2009 and 30 June 2009, she received the 1st, 2nd and 3rd dose of CERVARIX (IM deltoid) On 16 July 2009, 16 days after the 3rd dose of CERVARIX, this 25-year-old subject developed typhoid fever. The subject was hospitalised. The event resolved on 27 July 2009. The investigator considered that there was no reasonable possibility that the typhoid fever may have been caused by CERVARIX.

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=365938&WAYBACKHISTORY=ON


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166